New Randomized Trial Shows Promising Cognitive Gains in Long COVID Brain Fog Using Home-Based Light Therapy

Vielight Neuro RX Gamma device and irradiation configuration used in the randomized, double-blind, sham-controlled trial. The ...

Insurance data can help fill gaps between longer medical trials for patients up against the clock

Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...
Clinical Trials Arena on MSN

Axsome begins Phase III AXS-14 FORWARD trial for fibromyalgia management

Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...
Lupus Foundation of America

Phase 2b JASMINE trial of nipocalimab demonstrates positive results for treatment of systemic lupus erythematosus

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
News-Medical.Net on MSN

Digital coaching boosts asthma control and quality of life

While online coaching improves asthma management short-term, it does not sustain physical activity changes, highlighting the ...
The Manila Times

Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...
The Cardiology Advisor

Early Intensive BP Control Boosts Cardiovascular Protection in Older Patients

Early intensive BP control significantly reduces cardiovascular risk in older patients compared with delayed initiation of treatment.

Controversial US study on hepatitis B vaccines in Africa is cancelled

m project drew outrage over ethical questions about withholding vaccines proven to prevent disease ...
Daijiworld

Study finds STDP improves coronary slow flow in angina patients

Coronary slow flow phenomenon (CSFP) in patients with angina showed significant improvement with Shexiang Tongxin Dropping ...
Ophthalmology Times

First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial

SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( NCT06942572) evaluating SB-007 for the treatment of Stargardt disease.

Axsome Therapeutics, Inc.: Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...